Clinical Trials All MiniLM L6 V2

🚀 Sentence-Transformers モデル

このモデルは、sentence-transformers/all-MiniLM-L6-v2 をベースに構築され、文章の類似度評価や特徴抽出などのタスクに使用できます。

📦 モデル情報

🚀 クイックスタート

以下に、このモデルの使用例を示します。ウィジェットには、いくつかのソース文章と比較する文章が用意されています。

サンプルウィジェット 1

• ソース文章:
  • aprepitant prevention chemotherapy induce nausea vomit cinv0869130complete. The purpose of this study is to assess the efficacy and safety of recombinant human tissue plasminogen kinase derivatives for injection and alteplase in the treatment of patients with acute ischemic stroke within 4.5 hours.
• 比較文章:
  • Coronary Artery Diseases|Multivessel Coronary Artery Disease|Heart Diseases|Cardiovascular Diseases inclusion criteria1 patient 1 stenosis angiographic visually determine de novo lesion 50 d 3 major epicardial territory lad andor branch cx andor branch rca andor branch supply viable myocardium left main involvement2 patient hypoplastic rca absence descend posterior presence lesion lad cx territory include trial 3vd equivalent3 vessel size 15 mm diameter visually assess diagnostic angiogram4 patient chronic stable angina stabilize acute coronary syndrome inclusion criterion syntax study stable canadian cardiovascular society class 1 2 3 4 angina pectoris unstable braunwald class ib ic iib iic iiib iiic angina pectoris ischemia normal cardiac enzyme value prior enrollment patient atypical chest pain asymptomatic provide myocardial ischemia eg treadmill exercise test radionuclide scintigraphy stress echocardiography5 anatomical syntax score eligible6 patient amenable msct coronary angiography eg claustrophobia high heartrate amenable betablocker poor renal function etc discretion investigator7 patient inform nature study agree provision provide write informed consent approve ethical committee respective clinical siteexclusion criteria1 age 18 years2 unable informed consent3 know pregnancy time enrolment female childbeare potential menstruation 12 month take adequate contraceptive female breastfeed time enrolment4 prior pci cabg history coronary stent implantation5 evidence evolve ongoing acute myocardial infarction ami ecg andor elevated cardiac biomarker accord local standard hospital practice return normal limit time enrollment6 concomitant cardiac valve disease require surgical therapy reconstruction replacement7 single twovessel disease time heart team consensus8 atrial fibrillation significant arrhythmias9 know allergy iodinate contrast10 body mass index bmi 35 greater11 participation trial investigational drug device interrater agreement revascularization strategy heart team angiofirst algorithm ct algorithm interrater agreement assess cohens kappa kappa revascularization strategy heart team angiofirst algorithm base invasive syntax score ii ctfirst algorithm base noninvasive syntax score ii ffrct 95 confidence interval ci heart team meeting take place average 1 2 week afer patient enrollment level agreement decision make strategy base ct functional assessment decision make strategy base ct functional assessment ct algorithm group screen analysis nov 2017level agreement decision make strategy base ct functional assessment decision make strategy base ct functional assessment conventional angiography ct algorithm group screen analysis nov 2017level agreement decision make strategy base conventional angiography decision make strategy base ct functional assessment conventional angiography angio algorithm group screen analysis nov 2017interrater agreement revascularization strategy base conventional angiography ct functional assessment heart team angiofirst algorithm ctfirst algorithm screen analysis nov 2017anatomical syntax score calculation base noninvasive ge revolution ct visual heart team involve experienced coronary ct reader result syntax score ii screen analysis nov 2017anatomical syntax score calculation base noninvasive ge revolution ct visual core lab result syntax score ii screen analysis nov 2017anatomical syntax score calculation base invasive angiography visual heart team result syntax score ii screen analysis nov 2017anatomical syntax score calculation base invasive angiography visual core lab result syntax score ii screen analysis nov 2017ct base functional anatomy ffrct assess heartflow screen analysis nov 2017concordance syntax score strategy screen analysis nov 2017agreement coronary stenosis segment revascularize strategy screen analysis nov 2017
  • 'HIV Infections inclusion criterion 20 20 ideal weight height estimate frame size good health clinically significant abnormal finding physical examination medical history laboratory testsexclusion criterion history clinically significant disease history clinically significant allergy include drug allergy participate clinical trial 3 month prior study entry hiv infect hepatitis b c virus infect active significant infection prior exposure allergy know hypersensitivity pro 140 safety tolerability pro 140 60 day '
  • "Chemotherapy-Induced Nausea and Vomiting inclusion criterion patient naive emetogenic
    \ chemotherapy histologically cytologically confirm malignant disease schedule
    \ receive single dose moderately emetogenic chemotherapy study day 1 karnofsky
    \ score 60 greaterexclusion criterion patient schedule receive dose cisplatin
    \ patient receive abdominal pelvic radiation week prior 6 day initiation chemotherapy
    \ allergy study drug antiemetic take cyp3a4 substratesprohibite medication significant
    \ medical mental condition abnormal laboratory value platelet absolute neutrophil
    \ ast alt bilirubin creatinine number patient report vomiting number patient report
    \ vomiting overall phase cycle \n\n 1 overall phase 0120 hour post initiation
    \ mec cycle 1 number patient report complete response number patient report complete
    \ response vomiting use rescue medication overall phase cycle 1 overall phase
    \ 0120 hour post initiation mec cycle 1"

サンプルウィジェット 2

• ソース文章:
  • eribulin mesylate phase iv clinical trial korean patient metastatic locally advanced breast cancer. This study will treat patients with Metastatic Castration Resistant Prostate Cancer who have progressed following prior therapy. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.
• 比較文章:
  • End Stage Renal Disease inclusion criterion esrd patient age 18 80 year clinically stable judge treat physician 30 day prior enrollment demonstrate pertinent patient medical history physical examination laboratory testing hemodialysis therapy hdf 3 month immediately prior study enrollmentexclusion criterion inform consent provide significant psychiatric disorder mental disability condition interfere patient ability provide informed consent pregnant breastfeeding planning pregnant unstable vascular access associate risk low variable extracorporeal blood flow rate qb chronic liver disease know paraproteinassociate disease know bleed disorder eg gastrointestinal bleed colonic polyp small bowel angiodysplasia active peptic ulcer major bleeding episode ie soft tissue bleed blood stool joint damage retinal bleed extensive mucosal bleed exsanguination cerebral hemorrhage 12 week prior enrollment blood red blood cell transfusion 12 week prior enrollment clinical sign acute infection 4 week prior enrollment active cancer basal cell squamous cell skin cancer positive serology test human immunodeficiency virus hepatitis infection schedule plan intervention require hospitalization 1 week schedule livingdonor transplantation study period currently participate interventional clinical study participate interventional clinical study past 3 month interfere study reduction ratio lambda immunoglobulin free light chain λflc week 12reduction ratio kappa immunoglobulin free light chain kflc week 12reduction ratio chitinase3like protein 1 ykl40 week 12reduction ratio fibroblast growth factor 23 fgf23 week 12reduction ratio serum beta2 microglobulin β2 m week 12 change baseline midweek predialysis serum level λflc κflc ykl40 fgf23 ß2 m week 12 24change baseline midweek predialysis serum level pentraxin3 ptx3 high sensitivity creactive protein hscrp interleukin il6 interleukin10 il10 week 12 24percent change pre postdialysis midweek serum level hscrp week 12percent change pre postdialysis midweek serum level ptx3 week 12percent change pre postdialysis midweek serum level il6 week 12percent change pre postdialysis midweek serum level il10 week 12change baseline midweek predialysis serum level fibrinogen week 12 24change baseline midweek predialysis serum level albumin week 12 24single pool ktvurea week 24serum phosphorous week 24kidney disease quality life 36 kdqol36 baseline week 12 week 24dialysis symptom index dsi baseline week 12 week 24serum ferritin baseline week 12 week 24transferrin saturation tsat baseline week 12 week 2424hour urine output monthly basis month 1 month 2 month 3 month 4 month 5 month 6erythropoiesis stimulate agent esa responsiveness baseline week 4 week 8 week 12 week 16 week 20 week 24hemoglobin level baseline week 4 week 8 week 12 week 16 week 20 week 24esa dosage type administration frequency route baseline week 4 week 8 week 12 week 16 week 20 week 24intravenous iron dosage baseline week 4 week 8 week 12 week 16 week 20 week 24number adverse event hospitalization cardiovascular event infective episode week 1 week 24total patient death week 1 week 24
  • Skin Laxity inclusion criterion male female subject age 18 75 year old asa physical status classification system class class ii subject complaint skin laxity line low eyelid area understand accept obligation undergo procedure treatment area treat study participation absence physical condition unacceptable investigator female childbeare potential sexually active willing use approve method birth control study participation willing able comply protocol requirement include studyrequired imagesphotos assessmentsmeasurement return followup visit willing release right use study photo include publication able read understand sign date inform consent able communicate site video andor photograph event virtual followup visitexclusion criterion subject present asa physical status classification system class iii high festoon periorbital area prior cosmeticaesthetic filler hyaluronic acid polyllactic acid calcium hydroxylapatite et study treatment area past 12 month pregnant lactating plan pregnant study participation know hypersensitivity allergy tumescent anesthetic lidocaine epinephrine know hypersensitivity allergy ibuprofen nsaid previous surgery study treatment area active systemic local skin disease alter wound heal significant uncontrolled medical condition opinion investigator participation study compromise patient health history autoimmune disease exclude hashimotos thyroiditis know susceptibility keloid formation hypertrophic scar cancerous precancerous lesion area treat possess surgically implant electronic device ie pacemaker mental health illness dementia schizophrenia psychiatric hospitalization past year participation investigational study 30 day prior consent study participation subject opinion investigator appropriate candidate study day 180 number participant improvement low eyelid area determine mask qualitative assessment improvement low eyelid area determine mask qualitative assessment photograph 180days posttreatment compare baseline blind independent reviewer improvement assess base photograph take visit site 2d camera system 180day day 90 number participant improvement low eyelid area determine mask qualitative assessment improvement low eyelid area determine mask qualitative assessment photograph 90days posttreatment compare baseline blind independent reviewer improvement assess base photograph take visit site 2d camera system 90day
  • Breast Neoplasms|Breast Cancer inclusion criteria1 female age great equal 20 years2 patient histologically cytologically confirm carcinoma breast3 patient locally advance metastatic carcinoma breast4 patient receive prior chemotherapeutic regimen include antracycline taxane 2 regimen locally recurrent andor metastatic disease5 patient prove refractory recent chemotherapy 6 month therapy6 patient assessable lesion accord recist v 117 adequately maintain bone marrow function absolute neutrophil count anc great equal 15 x 109 l hemoglobin great equal 100 gdl hemoglobin 100 gdl acceptable correct erythropoietin transfusion platelet count great equal 100 x 109 l8 adequately maintain liver function total bilirubin equal 15 time upper limit normal uln alkaline phosphatasealp alanine aminotransferase alt aspartate aminotransferase ast equal 3 x uln case liver metastasis equal 5 x uln9 adequately maintain renal function serum creatinine equal 20 mgdl calculate creatinine clearance great equal 40 mlmin cockcroft gault formula10 resolution chemotherapy radiationrelated toxicity grade 1 severity low alopecia stable sensory neuropathy equal grade 211 eastern cooperative oncology group ecog performance status 0 212 life expectancy great equal 3 months13 patient willing able comply study protocol duration study14 patient provide write consent participate studyexclusion criteria1 patient receive chemotherapy radiation biologic immunotherapy hormonal therapy week treatment start palliative radiation enrolled2 pulmonary lymphangitic involvement result pulmonary dysfunction require active treatment include use oxygen3 patient brain subdural metastasis eligible complete local therapy discontinue use corticosteroid indication week start treatment study sign andor symptom brain metastasis stable week start study treatment4 patient meningeal carcinomatosis5 significant cardiovascular impairment myocardial infarction past month unstable angina history congestive heart failure nyha class iii iv cardiac arrhythmia qtc prolongation bazetts formula great 480 msec congenital long qt syndrome6 severeuncontrolle intercurrent illnessinfection require administration antibiotic injection7 patient process major surgery week participation clinical trial8 patient prior malignancy past year breast cancer treat nonmelanoma skin cancer carcinoma situ cervix excluded9 patient know positive hiv status10 patient receive genetic therapy investigational drug 4 week treatment start expect receive prohibit medication11 patient prior allergy halichondrin b derivative active ingredient diluting agent12 patient receive investigational product registration study13 patient pregnant possibly pregnant lactating14 patient agree practice contraception study periods15 patient participate clinical trial 4 week screening16 patient judge investigator sub investigator unsuitable inclusion number participant treatmentemergent adverse event teae treatmentemergent adverse event sae ae define harmful untoward sign include abnormal laboratory value etc symptom disease participant administer investigational product necessarily causal relationship treatment sae define ae life threaten result death result hospitalization initial prolonged result disability significant persistent permanent change impairment damage disruption participant body functionstructure physical activity quality life result congenital anomaly require intervention prevent permanent impairment damage teaes define event start date time administration dose study drug event present prior administration dose study drug increase severity study mean 376 month disease control rate dcr dcr define number participant complete response cr partial response pr stable disease sd response evaluation criterion solid tumor recist version 11 assess tumor response tumor response evaluate investigator cr define disappearance extranodal target lesion pathological lymph node decrease 10 millimeter mm short axis pr define 30 decrease sum long diameter sld target lesion take reference baseline sum diameter sd define sufficient shrinkage qualify pr sufficient increase qualify progressive disease sld increase 20 small value study include baseline small sld demonstrate absolute increase 5 mm lesion increase 2 mm 3 mm example qualify mean 376 month

サンプルウィジェット 3

• ソース文章:

  • 'safety study mt4666 subject alzheimer disease. This is a phase 1, randomized, open label, single-dose, replicate crossover clinical trial to compare the safety and pharmacokinetics of YH22162 in healthy male volunteers.

    Hypothesis: Study drug and comparator drug are showing equal pharmacokinetics.'

• 比較文章:
  • Alzheimer's Disease inclusion criterion probable alzheimer disease consistent national institute aging alzheimers association criterion diagnosis alzheimer disease mckhann et al 2011 mmse score 14 24 screening 12 26 baseline modify hachinski ischemic score mhis 4 screening appropriate caregiver available subject live home facility require continuous 24hour nursing careexclusion criterion diagnosis disease cause dementia diagnosis major depressive disorder define diagnostic statistical manual mental disorder fourth edition text revision dsmivtr year history current diagnosis psychosis history myocardial infarction unstable angina month screen history cerebrovascular disorder 18 month screen complication hepatic disorder renal dysfunction safety 2 fix dose evp6124 subject alzheimer disease criterion evaluation include adverse event clinical laboratory test vital sign body weight 12lead ecg columbia suicide severity rating scale cssrs week 56 change mini mental state examination mmse baseline week 52change neuropsychiatric inventory npi total score baseline week 52
  • 'Type 2 Diabetes inclusion criteria1 man nonpregnant woman 2865 year age2 diagnose t2d 3 years3 a1c 75 95 5980 mmolmol4 bmi 28 40 kgm25 oral oad metformin plus additional oad note half maximum label dose high tolerate change medication 12 week prior screening visit visit 1 refer ada standard medical care diabetes 2018 table 83 maximum approve daily dose noninsulin glucose lower agent 43 note subject sulfonylurea su glucoselowere drug diabetes sus permit study glipizide glimepiride dose half maximum label dosing exclusion study entry patient unwilling reduce dose su time dmr procedure describe protocol excluded6 agree use additional glucoselowere treatment eg liraglutide oad exception glyburide recommend study investigator case persistent hyperglycemia7 agree donate blood participation study8 able comply study requirement understand sign inform consent form9 woman childbeare potential wocbp acceptable method contraception study10 woman breastfeedingexclusion criteria1 diagnose type 1 diabetes t1d2 history diabetic ketoacidosis hyperosmolar nonketotic coma3 probable insulin production failure define fast c pep